Skip to Content
Showing 1-2 of 2

Sorted By:

  • DalGenE

    Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

  • Spire 1

    The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk

Page InfoPage
Showing trials 1-2 of 2